close
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2009 Jun;94(6):2031-6.
doi: 10.1210/jc.2008-1348. Epub 2009 Mar 10.

Glucoregulatory physiology in subjects with low-normal, high-normal, or impaired fasting glucose

Affiliations
Comparative Study

Glucoregulatory physiology in subjects with low-normal, high-normal, or impaired fasting glucose

Samuel Dagogo-Jack et al. J Clin Endocrinol Metab. 2009 Jun.

Abstract

Objective: We determined whether variations in fasting plasma glucose (FPG) within the nondiabetic range represent differences in insulin action or secretion.

Subjects and methods: Using results of the 75-g oral glucose tolerance test, we classified 39 adults (body mass index range 20-56 kg/m2) as having normal fasting glucose (NFG, <100 mg/dl, n = 24) or impaired fasting glucose (IFG, 100-125 mg/dl, n = 15). The NFG group was subdivided into low-NFG (<90 mg/dl, n = 11) and high-NFG (90-99 mg/dl, n = 13). The 2-h oral glucose tolerance test plasma glucose value was used to assign normal or impaired glucose tolerance (IGT) status. Insulin sensitivity was assessed by hyperinsulinemic euglycemic clamp, quantitative insulin sensitivity check index, and homeostasis model assessment of insulin resistance; beta-cell function was assessed by calculating the insulinogenic index, homeostasis model assessment, and the disposition index.

Results: Compared with low-NFG subjects, insulin sensitivity and glucose tolerance were lower among persons with isolated IFG and combined IFG-IGT. The hyperinsulinemic euglycemic clamp (micromol/kg x min(-1)/pmol/liter) was 0.109 +/- 0.011 in low-NFG subjects, 0.088 +/- 0.009 in IFG subjects (P = 0.04), and 0.022 +/- 0.003 in IFG-IGT subjects (P = 0.0014). The spread in FPG from 70-125 mg/dl was associated with a greater than 3-fold difference in insulin sensitivity. Compared with low-NFG subjects, the disposition index decreased by 32.8% in high-NFG subjects (P = 0.08), by 45.6% in subjects with isolated IFG (P < 0.02), and by 49.8% (P < 0.02) in those with combined IFG-IGT.

Conclusion: Compared with persons with low-NFG, those with IFG or combined IFG-IGT have significant alteration of glucoregulatory physiology, whereas high-NFG (pre-prediabetes) status might portend nascent glucoregulatory perturbations.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Plasma glucose (A) and insulin (B) levels during the OGTT. To convert glucose from milligrams per deciliter to millimoles per liter, multiply by 0.05551. To convert insulin from microunits per milliliter to picomoles per liter, multiply by 6.0.
Figure 2
Figure 2
Assessment of insulin sensitivity and secretion in subjects with low-NFG, high-NFG, pure IFG, and combined IFG-IGT. A, ISI-clamp; B, HOMA-IR (*, P = 0.04 compared with low-NFG; **, P = 0.0027–0.0011, compared with other groups; ***, P = 0.043 to <0.0001, compared with other groups); C, correlation of insulin sensitivity vs. FPG in nondiabetic men (•) and women (○). The r value shown is the Spearman correlation coefficient. D, DI, calculated as the product of acute insulin secretion (ΔI0–30/ΔG0–30) and insulin sensitivity (ISI-clamp). #, Significantly lower than low-NFG (P < 0.02).

References

    1. Vendrame F, Gottlieb PA 2004 Prediabetes: prediction and prevention trials. Endocrinol Metab Clin North Am 33:75–92, ix - PubMed
    1. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403 - PMC - PubMed
    1. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR 2006 Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096–1105 - PubMed
    1. World Health Organization 1985 Diabetes mellitus: Report of a World Health Organization Study Group. Tech Rep Ser 727. Geneva: World Health Organization - PubMed
    1. Weyer C, Bogardus C, Mott DM, Pratley RE 1999 The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787–794 - PMC - PubMed

Publication types